Clinical Trials Directory

Trials / Unknown

UnknownNCT03634189

Cannabidiol in Patients With Heart Failure Failure in AHA/ACC Stages A-C

Phase I, Single Center, Open-label Study of Cannabidiol in Patients With Heart Failure in AHA/ACC Stages A-C

Status
Unknown
Phase
Phase 1
Study type
Interventional
Enrollment
20 (estimated)
Sponsor
Instituto de Cardiología y Medicina Vascular Hospital Zambrano-Hellion Tec Salud · Academic / Other
Sex
All
Age
30 Years – 75 Years
Healthy volunteers
Not accepted

Summary

Cannabidiol in heart failure

Conditions

Interventions

TypeNameDescription
DRUGCannabidiolPatients with ACC/AHA stage A-C will receive 5 mg/kg to a maximum tolerated dose of 25 mg/kg PO BID of Cannabidiol

Timeline

Start date
2021-03-01
Primary completion
2021-09-01
Completion
2021-12-01
First posted
2018-08-16
Last updated
2020-08-05

Source: ClinicalTrials.gov record NCT03634189. Inclusion in this directory is not an endorsement.

Cannabidiol in Patients With Heart Failure Failure in AHA/ACC Stages A-C (NCT03634189) · Clinical Trials Directory